GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Price-to-Funds-From-Operations

BioLine Rx (XTAE:BLRX) Price-to-Funds-From-Operations : (As of May. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BioLine Rx (XTAE:BLRX) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.